Required Sublicensing. If Medicenna is unable or unwilling to serve or develop a potential market or market territory for which there is a company, with adequate resources, capabilities and expertise, willing to be a sublicensee, Medicenna will, at Stanford's request, attempt to negotiate in good faith a Sublicense with any such sublicensee. Stanford would like licensees to address unmet needs, such as those of neglected patient populations or geographic areas, giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing world.
Appears in 3 contracts
Samples: Exclusive Equity Agreement (Medicenna Therapeutics Corp.), Exclusive Equity Agreement (Medicenna Therapeutics Corp.), Exclusive Equity Agreement